✦ LIBER ✦

Antibody persistence at 18–20 months of age and safety and immunogenicity of a booster dose of a combined DTaP–IPV//PRP∼T vaccine compared to separate vaccines (DTaP, PRP∼T and IPV) following primary vaccination of healthy infants in the People's Republic of China

✍ Scribed by Rong Cheng Li; Feng Xiang Li; Yan Ping Li; Qi Ming Hou; Chang Gui Li; Ya Nan Li; Fu Sheng Chen; Xue Zhong Hu; Wen Bin Su; Shu Min Zhang; Han Hua Fang; Qiang Ye; Tian De Zeng; Tao Xuan Liu; Xiu Bi Li; Yun Neng Huang; Man Ling Deng; Yan Ping Zhang; Esteban Ortiz

Book ID: 116964374
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 563 KB
Volume: 29
Category: Article
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2011.09.131

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Immunogenicity and safety study of a new

Immunogenicity and safety study of a new DTaP–IPV–Hep B–PRP-T combined vaccine compared to a licensed DTaP–IPV–Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants

✍ Pope Kosalaraksa; Usa Thisyakorn; Suwat Benjaponpitak; Kulkanya Chokephaibulkit; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 290 KB

Antibody persistence at 18–20&#xa0;months of age and safety and immunogenicity of a booster dose of a combined DTaP–IPV//PRP∼T vaccine compared to separate vaccines (DTaP, PRP∼T and IPV) following primary vaccination of healthy infants in the People's Republic of China

Antibody persistence at 18–20 months of age and safety and immunogenicity of a booster dose of a combined DTaP–IPV//PRP∼T vaccine compared to separate vaccines (DTaP, PRP∼T and IPV) following primary vaccination of healthy infants in the People's Republic of China